Capital Fund Management (CFM)’s Apellis Pharmaceuticals APLS Stock Holding History

Capital Fund Management (CFM)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-68,112	Closed	-$2.74M	–	2064
2026 Q1	$2.74M	Buy	+68,112	New	+$1.47M	0.01%	1203
2025 Q1	–	Sell	-121,433	Closed	-$3.87M	–	1962
2024 Q4	$3.87M	Sell	121,433 -121,801	-50%	-$3.66M	0.01%	1204
2024 Q3	$7.01M	Buy	243,234 +41,747	+21%	+$1.55M	0.02%	861
2024 Q2	$7.73M	Buy	+201,487	New	+$9.12M	0.02%	786
2023 Q1	–	Sell	-12,884	Closed	-$666K	–	1543
2022 Q4	$666K	Buy	+12,884	New	+$683K	﹤0.01%	1213
2022 Q2	–	Sell	-10,620	Closed	-$540K	–	1405
2022 Q1	$540K	Buy	+10,620	New	+$469K	﹤0.01%	1294

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Capital Fund Management (CFM)'s APLS Position: Q2 2026 in Review

Capital Fund Management (CFM) sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 68,112 shares — an estimated $2.74M sold.

Capital Fund Management (CFM) first reported a position in APLS in Q1 2022 and held it in 6 quarters. The position peaked at $7.73M in Q2 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Capital Fund Management (CFM) reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Capital Fund Management (CFM) sold 68,112 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.74M.
Capital Fund Management (CFM) first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Capital Fund Management (CFM)'s Apellis Pharmaceuticals position peaked at $7.73M in Q2 2024.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.